Edwards Lifesciences Corp. closed 26.14% below its 52-week high of $96.12, which the company reached on March 28th.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

The stock's rise snapped a three-day losing streak.

Learn more about whether Edwards Lifesciences Corporation or Stryker Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Matthew Edwards joined Brown Rudnick as a transactions partner in its global life sciences practice group in London, the firm ...

U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...

Edwards Lifesciences Co. (NYSE:EW – Get Free Report) has been given a consensus rating of “Hold” by the twenty-six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One ...